Irati Zubiri
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Irati Zubiri has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Carmen Sanmartín
Department of Pharmaceutical Sciences, Universidad de Navarra, 31008 Pamplona, Spain
1 shared publication - Daniel Plano
Department of Pharmaceutical Sciences, Universidad de Navarra, 31008 Pamplona, Spain
1 shared publication - Eduardo Angulo-Elizari
University of Navarra, School of Pharmacy and Nutrition, Department of Pharmaceutical Sciences, Irunlarrea 1, 31008, Pamplona, Spain
1 shared publication - Leire Gaviria-Soteras
Department of Pharmaceutical Sciences, University of Navarra, Irunlarrea 1, E-31008 Pamplona, Spain
1 shared publication - Sandra Ramos-Inza
Centro de Investigaciones Biológicas “Margarita Salas” (CIB-CSIC), Madrid, Spain
1 shared publication
Latest Publications
- Open Access
- 18 September 2023
- Published by MDPI AG in Drugs and Drug Candidates
- Vol. 2 (3) , 728-769
Unmasking the Warburg Effect: Unleashing the Power of Enzyme Inhibitors for Cancer Therapy
The Warburg effect (or aerobic glycolysis), which was first described in 1926 by Otto Heinrich Warburg, consists of the change in glucose metabolism in cancer cells. In normal cells, glucose metabolism finalizes in the mitochondria through oxidative phosphorylation (OXPHOS) in the presence of oxygen. However, the Warburg effect describes a change in the glucose metabolism in cancer cells, consuming excess glucose and converting it into lactate independently of the presence of oxygen. During this process, a wide variety of enzymes can modify their expression and activity to contribute to the mechanism of deregulated cancer metabolism. Therefore, the modulation of enzymes regulating aerobic glycolysis is a strategy for cancer treatment. Although numerous enzymes play a role in regulating aerobic glycolysis, hexokinase 2 (HK2), pyruvate dehydrogenase kinase (PDK), pyruvate kinase (PK), and lactate dehydrogenase (LDH) are worth mentioning. Numerous modulators of these enzymes have been described in recent years. This review aims to present and group, according to their chemical structure, the most recent emerging molecules targeting the above-mentioned enzymes involved in the Warburg effect in view of the future development of cancer treatments.
- 18 September 2023
- Published by MDPI AG in Drugs and Drug Candidates
- Vol. 2 (3) , 728-769
Open AccessUnmasking the Warburg Effect: Unleashing the Power of Enzyme Inhibitors for Cancer Therapy
The Warburg effect (or aerobic glycolysis), which was first described in 1926 by Otto Heinrich Warburg, consists of the change in glucose metabolism in cancer cells. In normal cells, glucose metabolism finalizes in the mitochondria through oxidative phosphorylation (OXPHOS) in the presence of oxygen. However, the Warburg effect describes a change in the glucose metabolism in cancer cells, consuming excess glucose and converting it into lactate independently of the presence of oxygen. During this process, a wide variety of enzymes can modify their expression and activity to contribute to the mechanism of deregulated cancer metabolism. Therefore, the modulation of enzymes regulating aerobic glycolysis is a strategy for cancer treatment. Although numerous enzymes play a role in regulating aerobic glycolysis, hexokinase 2 (HK2), pyruvate dehydrogenase kinase (PDK), pyruvate kinase (PK), and lactate dehydrogenase (LDH) are worth mentioning. Numerous modulators of these enzymes have been described in recent years. This review aims to present and group, according to their chemical structure, the most recent emerging molecules targeting the above-mentioned enzymes involved in the Warburg effect in view of the future development of cancer treatments.